Insights - We are looking forward to December catalysts and watching two companies with near term readouts that we think the market is under appreciating. Both present … Continue Reading
Read nowInsights - Achillion Pharmaceuticals (ACHN) announced after the close on Tuesday a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, of Johnson & Johnson (JNJ), to develop … Continue Reading
Read nowRecap - Merry Christmas and Happy Holidays! Wishing you and yours a spectacular 2015! We were one and one in last week’s healthcare recap. The v-bottom played out as many expected, … Continue Reading
Read nowResearch - Achillion Pharmaceuticals (ACHN) reported anticipated data for its nucleotide inhibitor ACH-3422 this morning alongside data from a phase 2 proxy study.
PremiumRecap - We’re in the throes of yet another sharp “V-bottom” for the S&P 500 (SPX), a rapid drop followed by a rip-your-face off rally – the 10th occurrence … Continue Reading
Read nowRecap - Johnson & Johnson (JNJ) is shelling out $1.75 billion to acquire Alios Biopharma, a private developer of therapeutics for viral diseases. Alios’ lead drug asset … Continue Reading
Read nowInsights - Johnson & Johnson (JNJ) is shelling out $1.75 billion to acquire Alios Biopharma, a private developer of therapeutics for viral diseases. Alios’ lead drug asset is compound … Continue Reading
Read now
